Latest news in cancer
Inotuzumab ozogamicin is approved by the USFDA for pediatric patients with acute lymphoblastic leukemia
6th March 2024: Inotuzumab ozogamicin (Besponsa, Pfizer) has been granted approval by the Food and Drug Administration for the treatment of relapsed or...
Understanding relations between MRD and CAR T-Cell therapy
What is MRD in cancer treatment? Measurable Residual Disease, or MRD, is the name for the very few cancer cells that stay in the body after or during...
Mesenchymal stem cell therapy in neurological disorders
Neurological diseases are big problems around the world because they cause a lot of death and disability. Traditional treatments haven’t always worked,...
Orphan drug designation is given by FDA to CART T-Cell Therapy A2B530 for the treatment of colorectal cancer
In March 2024, a news release said that A2B530 (A2 Biotherapeutics), a CAR T-cell therapy, had been given Orphan Drug Designation to treat colorectal cancer...
Iovance’s Amtagvi is approved by USFDA as first T-cell therapy for a solid tumor
Iovance Biotherapeutics’ first-of-its-kind immunotherapy was approved by the FDA. This means that T-cell therapy, which has changed the way some types of...
Amivantamab-vmjw is approved by the USFDA for EGFR exon 20 insertion-mutated non-small cell lung cancer indications
The Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in combination with carboplatin and pemetrexed on March 1, 2024....
Osimertinib with chemotherapy is approved by the USFDA for EGFR-mutated non-small cell lung cancer
The Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) in combination with platinum-based chemotherapy for patients...
Lifileucel is approved by the USFDA for unresectable or metastatic melanoma
The Food and Drug Administration granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics, Inc.) on February 16, 2024. This approval is for...
Tepotinib is approved by the USFDA for metastatic non-small cell lung cancer
The Food and Drug Administration officially approved tepotinib (Tepmetko, EMD Serono, Inc.) on February 15, 2024, for adult patients with metastatic non-small...
Irinotecan liposome is approved by the USFDA for first-line treatment of metastatic pancreatic adenocarcinoma
The Food and Drug Administration approved irinotecan liposome (Onivyde, Ipsen Biopharmaceuticals, Inc.) with oxaliplatin, fluorouracil, and leucovorin on...
Erdafitinib is approved by USFDA for locally advanced or metastatic urothelial carcinoma
Erdafitinib (Balversa, Janssen Biotech) was approved by the Food and Drug Administration on January 19, 2024, for adult patients with FGFR3 genetic changes who...
Pembrolizumab with chemoradiotherapy is approved by the USFDA for FIGO 2014 Stage III-IVA cervical cancer
The Food and Drug Administration authorized pembrolizumab (Keytruda, Merck) in combination with chemoradiotherapy (CRT) for patients with FIGO 2014 Stage...
Enfortumab vedotin-ejfv with pembrolizumab is approved by USFDA for locally advanced or metastatic urothelial cancer
As of December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) along with pembrolizumab (Keytruda,...
Belzutifan is approved by USFDA for advanced renal cell carcinoma
The Food and Drug Administration granted approval for belzutifan (Welireg, Merck & Co., Inc.) on December 14, 2023, for patients with advanced renal cell...
Eflornithine is approved by USFDA for adult and pediatric patients with high-risk neuroblastoma
The FDA approved eflornithine (IWILFIN, USWM, LLC) on December 13, 2023, to lower the risk of relapse in adults and children with high-risk neuroblastoma...
Pirtobrutinib is approved by the USFDA for chronic lymphocytic leukemia and small lymphocytic lymphoma
The Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) on December 1, 2023, for adults with chronic...
Nirogacestat is approved by the USFDA for desmoid tumors
The Food and Drug Administration authorized nirogacestat (OGSIVEO, SpringWorks Therapeutics, Inc.) on November 27, 2023, for adult patients with advancing...
Enzalutamide is approved by the USFDA for non-metastatic castration-sensitive prostate cancer with biochemical recurrence
The FDA has authorized enzalutamide for the treatment of non-metastatic castration-sensitive prostate cancer in cases of biochemical recurrence. The Food and...
Capivasertib with fulvestrant is approved by the USFDA for breast cancer treatment
Capivasertib (Truqap, AstraZeneca Pharmaceuticals) in combination with fulvestrant was approved by the Food and Drug Administration on November 16, 2023, for...
Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma
The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on...
Repotrectinib is approved by the USFDA for ROS1-positive non-small cell lung cancer
The Food and Drug Administration authorized repotrectinib (Augtyro, Bristol-Myers Squibb Company) for locally advanced or metastatic ROS1-positive non-small...
Fruquintinib is approved by the USFDA in refractory metastatic colorectal cancer
The Food and Drug Administration approved fruquintinib (Fruzaqla, Takeda Pharmaceuticals, Inc.) on November 8, 2023, for adult patients with metastatic...
FDA revises pembrolizumab’s indication for gastric cancer
The Food and Drug Administration updated the approved use of pembrolizumab (Keytruda, Merck) in combination with trastuzumab, fluoropyrimidine, and...
Pembrolizumab with chemotherapy is approved by the USFDA for biliary tract cancer
On October 31, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) to be used with gemcitabine and cisplatin to treat biliary tract...
Toripalimab-tpzi is approved by the FDA for nasopharyngeal carcinoma
In October 2023, the FDA approved toripalimab-tpzi (LOQTORZ, Coherus BioSciences, Inc.) with cisplatin and gemcitabine as the first-line treatment for people...
Stem Cell Therapy for Diabetes: A Promising Treatment Approach
March 2024: Stem cell therapy has emerged as a promising treatment option for diabetes mellitus, potentially addressing the obstacles that patients encounter....
Revolutionizing Multiple Myeloma Treatment through CAR T-Cell Therapy in China
Feb 2024: China’s pioneering efforts in creating breakthrough cancer therapeutics have gained traction with the introduction of chimeric antigen receptor...
Mesenchymal stem cells (MSC) and platelet-rich plasma (PRP) therapy in the treatment of knee osteoarthritis
Feb 2024: Mesenchymal stem cells (MSCs) and platelet-rich plasma (PRP) therapy have shown potential in treating knee osteoarthritis (KOA) in China. A...
Tumor-Infiltrating Lymphocyte (TIL) Therapy in China
Feb 2024: Tumor-infiltrating lymphocyte (TIL) therapy treatment is a potential method that utilizes the body’s immune system to fight solid tumors. This...
The Life-Changing Treatment for Blood Cancer Finally Exposed!
Blood cancer is a type of cancer that affects both the blood and bone marrow. It is the fifth most common type of cancer in the world, with around 1.24 million...
Clinical Trials Of CAR T-Cell Therapy In China Has Shown Remarkable Success
CAR T-Cell therapy trials in China 2024 has been a game-changer for CAR T-Cell therapy in China! Witness remarkable success stories from clinical trials,...
A Closer Look At Recent Cancer Clinical Trials In China And New Cancer Drug Approved
This article closely examines cancer clinical trials in China in the past few years, focusing on major findings and areas of progress. It also discusses newly...
NMPA Approves FUCASO: Multiple Myeloma Treatment In China
FUCASO treatment in China The overall response rate of this revolutionary cancer therapy named FUCASO is 96%. The NMPA’s approval marks a turning point...
Breast Cancer Treatment Costs in India in 2025
Cost of breast cancer treatment in India in 2025 Breast cancer accounts for 31% of all cancers diagnosed in Indian women, making it the leading...
How is PET CT scanning changing the lives of cancer patients worldwide?
A PET scan is a ray of hope in the fight against cancer. If your doctor suspects a case of cancer, they might use this imaging method for an accurate...
Free Cancer Treatment In China Without Breaking The Bank: A Guide For Those Who Need It Most
Free cancer treatment in China is providing hope and healing to people in need. So, if you are unable to opt for cancer treatment because of its extensive...
Need help? Our team is ready to assist you.
We wish a speedy recovery of your dear and near one.